---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Radical cystectomy"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Radical cystectomy. Topics: Guideline recommendation: radical cystectomy as the standard option for BCG-unresponsive disease; Standard of care, morbidity, and deferral of surgery; Upfront radical cystectomy compared with bladder-sparing therapy: multicenter retrospective cohort; Radical cystectomy compared with bladder-sparing therapy: prospective CISTO cohort, 12-month results; 3 further topics. 7 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/radical-cystectomy"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Radical cystectomy

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 Radical Cystectomy

<a id="topic-2.2.2.1.1-1"></a>

### Guideline recommendation: radical cystectomy as the standard option for BCG-unresponsive disease

> “Patients with BCG-unresponsive disease are unlikely to respond to further BCG therapy; RC is therefore the standard and preferred option.”
> “Offer an RC to patients with BCG-unresponsive tumours.”
> “Early RC is recommended in patients with BCG-unresponsive tumours and should be considered in BCG-relapsing HG tumours, as discussed in Section 7.8 and Table 7.5.”
> “A delay in RC may lead to decreased disease-specific survival”
> “Treatments other than RC must be considered oncologically inferior in patients with BCG-unresponsive tumours.”
> “However, the potential benefit of RC must be weighed against its risks, morbidity, and impact on quality of life (QoL) and discussed with patients in a shared decision-making process.”
> “Offer patients with BCG-unresponsive tumours, who are not candidates for RC due to comorbidities, or who decline RC, preservation strategies (intravesical chemotherapy, chemotherapy and microwave-induced hyperthermia, electromotive administration of chemotherapy, intravesical- or systemic immunotherapy; preferably within clinical trials).”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

<a id="topic-2.2.2.1.1-2"></a>

### Standard of care, morbidity, and deferral of surgery

> “Standard treatment for patients with BCG-unresponsive NMIBC is radical cystectomy, which carries substantial morbidity and mortality; the incidence of complications is 35% to 40% and the 90-day mortality rate is 4.7%”

Source: [Colbert et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11961324/)

> “Major guidelines recommend radical cystectomy (RC) with urinary diversion as the standard‐of‐care for BCG‐unresponsive NMIBC due to higher propensity for disease recurrence and progression”
> “Cancer‐specific survival (CSS) is >80% after RC is performed for NMIBC”
> “However, many patients defer RC due to concerns about perioperative morbidity and its impact on quality of life (QoL).”

Source: [Taylor et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11745998/)

> “Although radical cystectomy is the preferred treatment for BCG-unresponsive disease”
> “surgery is associated with considerable morbidity and mortality risks, which are particularly germane for patients with this disease, who are often older and have comorbid conditions”

Source: [Moyer et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12721500/)

<a id="topic-2.2.2.1.1-3"></a>

### Upfront radical cystectomy compared with bladder-sparing therapy: multicenter retrospective cohort

> “Among 578 patients, 28% underwent upfront RC and 72% received BST. The median (interquartile range) follow‐up was 50 (20–69) months. There were no statistically significant differences in metastasis‐free survival, cancer‐specific survival, or overall survival between treatment groups.”
> “RC was performed in 31.7% in the BST group and nodal disease was found in 13% compared with 4% in upfront RC (P = 0.030).”
> “There were no significant differences in MFS (HR 0.88, 95% CI 0.53–1.46; P = 0.62), CSS (HR 0.91, 95% CI 0.54–1.53; P = 0.73), or OS (HR 1.31, 95% CI 0.91–1.90; P = 0.15) between patients who received upfront RC compared to those receiving BST at time of diagnosis of BCG‐unresponsive NMIBC (Fig. 1).”
> “Although adverse oncological outcomes began to rise 12 months after diagnosis, the rate of dying from bladder cancer were similar at 14% in both the upfront RC and BST groups at 5 years.”
> “The low rates of metastasis and death for patients who underwent BST are reassuring, but comparison with RC is impacted by selection bias.”

Source: [Taylor et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11745998/)

<a id="topic-2.2.2.1.1-4"></a>

### Radical cystectomy compared with bladder-sparing therapy: prospective CISTO cohort, 12-month results

> “Of 570 participants (mean age 71.4 years; 21% female), 371 selected BST and 199 selected RC. Physical function was significantly worse in the RC arm at 3 months; by 9 months, there was no difference between arms, and at 12 months, physical function did not differ (ATE, 0.9; 95% CI, –0.6 to 2.4; P = .22).”
> “Cancer-specific survival was 99% for BST versus 96% for RC (wRR, 0.99; 95% CI, 0.97 to 1.01). RC was associated with a higher risk of adverse events and serious adverse events, including a 90-day mortality rate of 2.5%.”
> “Among participants who selected RC, 15 (8.0%) experienced prolonged hospitalization after their RC, 57 (30%) were readmitted within 90 days, and five (2.5%) died within 90 days”
> “Upstaging occurred among 22% of patients undergoing RC, reflective of the higher cancer severity in the RC arm and well-established understaging of bladder cancer with imaging and endoscopy.”

Source: [Gore et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12707586/)

<a id="topic-2.2.2.1.1-5"></a>

### Timing of radical cystectomy after BCG failure

> “Five-year overall and cancer specific survival was similar in groups 1 and 2 at 80% and 85%, respectively, at approximately equivalent followups. Median bladder retention was 1.7 years longer in group 2 (p <0.001).”
> “On multivariate Cox regression analysis delayed cystectomy in group 2 did not convey a significant hazard for all cause mortality after cystectomy (HR 1.08, p = 0.808).”

Source: [Haas et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26807928/)

> “In the historical cohort the 85 patients with documented T1 recurrence were initially treated with repeat transurethral resection and intravesical bacillus Calmette-Guerin.”
> “At 5 years after T1 recurrence, the cumulative incidence of progression to T2 disease was 71% (95% CI 61%, 81%) and the cumulative incidence of death from disease was 48% (95% CI 39%, 60%).”
> “In this cohort 65 of the 129 patients with recurrent T1 underwent immediate radical cystectomy. At 5 years after T1 recurrence, the cumulative incidence of progression to muscle invasive disease was 28% (95% CI 20%, 38%) and the cumulative incidence of death from disease was 31% (95% CI 22%, 42%).”

Source: [Raj et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17382713/)

<a id="topic-2.2.2.1.1-6"></a>

### Early complications of radical cystectomy: standardized reporting in 1,142 procedures

> “Sixty-four percent (735/1142) of patients experienced a complication within 90 d of surgery.”
> “Overall, the highest grade of complication was grade 0 in 36% (n=407), grade 1-2 in 51% (n=582), and grade 3-5 in 13% (n=153). Gastrointestinal complications were most common (29%), followed by infectious complications (25%) and wound-related complications (15%). The 30-d mortality rate was 1.5%.”

Source: [Shabsigh et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/18675501/)

<a id="topic-2.2.2.1.1-7"></a>

### Ninety-day mortality after radical cystectomy: muscle-invasive disease, National Cancer Database

> “Among 7922 patients, 90-day mortality was 7.6% (8.0% for lower and 6.7% for higher volume hospitals).”
> “The model predicted 25% of patients had a 90-day mortality risk higher than 10%, and observed 90-day mortality in this group was 14.0% (95% CI = 12.5% to 15.6%).”

Source: [Marqueen et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6349610/)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
